This content is restricted.
Brief
On March 15, 2024, the National Health Surveillance Agency (Anvisa) concluded its project "Monitoring and Periodic Analysis of Advanced Therapy Products: Reevaluation of Benefit-Risk Profile and Social Transparency". The agency monitored five advanced therapy products registered since 2020, analyzing their efficacy and safety.
Highlights content goes here...
This content is restricted.

RADA.AI
Hello! I'm RADA.AI - Regulatory Analysis and Decision Assistance. Your Intelligent guide for compliance and decision-making. How can i assist you today?
Suggested